Date: 20080110
Docket: T-1415-04
Citation: 2008 FC 33
Ottawa, Ontario, this 10th day of January, 2008
PRESENT: The Honourable Barry Strayer, Deputy Judge
BETWEEN:
DORA SFETKOPOULOS, DAVID
MCGREGOR,
PRISCILLA LAVELL, EUGENE HARACK, ROBIN
TURNEY,
RONALD FOLZ, MICHAEL GIBBISON, TIMOTHY
DEGANS,
MARK HUKULAK, LEONARD SISSON, PAUL
MANNING,
RON REID, RON SPECK, JOHN LOBRAICO, EDDIE
WALLACE,
MICHAEL DELARMEE, RONALD GEORGE WILSON,
and JEFFREY LONG
Applicants
and
THE
ATTORNEY GENERAL OF CANADA
Respondent
REASONS FOR JUDGMENT AND JUDGMENT
INTRODUCTION
[1]
This
is an application for judicial review. The Applicants ask that the Court
declare invalid subsection 41(b.1) of the Marihuana Medical Access
Regulations, SOR/2001-227 (MMAR). A request in the original application for
mandamus requiring the Minister of Health to authorize Carasel Harvest
Supply Corporation (Carasel) to be a designated producer of medicinal cannabis
for all of the Applicants has been withdrawn. Instead the Applicants ask that
the matter be referred back to the Minister for reconsideration. The Applicants
also request that this Court retain supervisory jurisdiction over Health Canada’s
implementation of a revised process for allowing a single designated producer
of medical marihuana to produce for more than one medical user.
FACTS
[2]
The
MMAR permit certain persons to apply to the Minister of Health for
authorization to possess (ATP) dried marihuana. The application must show that
the applicant suffers from a terminal disease specified in the Regulations, or
from symptoms associated with such diseases, or certain other conditions where
the medical opinions certify that marihuana might mitigate such conditions. The
Regulations limit the lawful sources of supply of dried marihuana for the ATP
holder to marihuana produced by that holder or by a person designated by him,
or from a licensed dealer. If the ATP holder produces for himself he must have
a personal production license (PPL). If he obtains from a person he designates,
that person must obtain a designated-person production license (DPPL). That
license holder can obtain a license to produce for only one user (MMAR,
subsection 41(b.1), and may not produce marihuana in common with more than two
other holders of DPPL’s (MMAR, section 54.1). There is one licensed dealer in
Canada, Prairie Plant Services (PPS) which grows marihuana under contract with
the Government of Canada in a mine in Flin Flon, Manitoba. That
production is further processed in Saskatoon, Saskatchewan.
[3]
All
of the present Applicants applied to the Minister of Health to designate as
their producer Carasel of Smith Falls, Ontario. The manager of Carasel was
licensed to produce marihuana for one of the Applicants and her husband was
licensed to produce for another. Otherwise the Applicants’ request for licenses
designating Carasel as their DPPL were refused as advised in a letter dated May
20, 2004 to Carasel from the Director General, Drug Strategy and Controlled
Substances Program of Health Canada basing the decision on subsection 41(b) of
the MMAR. This subsection read as follows:
The
Minister shall refuse to issue a designated-person production license [if]
…
(b)
the designated person would be the holder of more than one licence to
produce;
…
|
Le
ministre refuse de délivrer la licence de production à titre de personne désignée:
…
b)
dans le cas où la personne désignée deviendrait titulaire de plus d’une
licence de production si la licence était délivrée;
…
|
(In point of fact, subsection 41(b) had by
then been found invalid as described below, and had been replaced by an
identical provision re-enacted as subsection 41(b.1).)
[4]
This
issue has a substantial history. Prior to the adoption of the MMAR there was no
authorized system for persons with severe medical conditions to obtain dried
marihuana. The possession of such marihuana was prohibited by the Controlled
Drugs and Substances Act, S.C. 1996, c. 19, s. 4 and by the Narcotic
Control Act, R.S.C. 1985, c. N-1, s. 6. While there had been some other
cases touching on this problem, the first leading authority was the case of R.
v. Parker (2000), 49 O.R. (3rd) 481 decided by the Ontario Court
of Appeal in July, 2000. Mr. Parker suffered from epilepsy and found that
smoking marihuana helped him avoid serious symptoms. He was charged with
possession and cultivation of marihuana. Evidence from his doctor and from
experts generally supported the beneficial effects of marihuana, particularly
for those suffering from epilepsy. The trial judge had found that the evidence
established the therapeutic effects of marihuana in treatment of epilepsy and that
its denial to the defendant was an infringement of section 7 of the Charter.
He therefore granted an exemption to the defendant from the statutes
prohibiting possession of marihuana. On appeal, the Ontario Court of Appeal
confirmed that section 4 of the Controlled Drugs and Substances Act (the
Narcotics Control Act having been repealed in the interim) was invalid
in that it deprived Mr. Parker of his rights to liberty and security contrary
to section 7 of the Charter. In its judgment of July 31, 2000, the Court
declared section 4 invalid but suspended the declaration for a year to allow
the government to provide some substitute arrangement consistent with the Court’s
decision. One day before the expiry of that suspension, on July 30, 2001, the
Governor in Council enacted the MMAR. Those regulations, while providing a
system for medical users with ATP’s to grow and possess marihuana legally or to
obtain it legally from a DPPL, drastically restricted the use of DPPL’s. The MMAR
prohibited compensation being paid to a designated producer and more seriously,
limited the production of a DPPL to one customer. These regulations came under
attack in Hitzig v. Canada (2003), 171 CCC (3rd) 18 in the
Superior Court of Ontario. On January 9, 2003, that Court found the regulations
limiting an ATP’s supply to either marihuana grown by the user or by a DPPL
(where the DPPL could not be paid and could only grow for one user) were so
restrictive as to force many users to obtain marihuana illicitly on the black
market. (PPS had not at that time been licensed as a dealer to provide its
production to users: at that time its production was being used for research
only). The Superior Court held the regulations to infringe Mr. Hitzig’s rights
of liberty and security under section 7 of the Charter. The learned
judge found that the restrictions were not in accordance with the principles of
fundamental justice because there was no rational connection between the
restrictions and the state’s interests. In response, in July, 2003, Health
Canada developed the Interim policy on Distribution of Marihuana
Seeds and Dried Marihuana Product for Medical Purposes in Canada. This
policy, combined with some amendments to the MMAR, allowed people with an ATP
to obtain dried marihuana or a marihuana seed directly from PPS. While this was
announced before the hearing by the Ontario Court of Appeal of Hitzig
the Court was not asked to take into account the constitutionality of that
policy or whether it affected the constitutionality of the regulations held by
the Superior Court of Ontario to be invalid. The Ontario Court of Appeal
rendered its judgment in Hitzig on October 7, 2003. It held various
aspects of the MMAR to be invalid. The portions of concern to us are those relating
to access to supply. The Court struck down the requirements that a DPPL not be
compensated and that he be confined to one customer. The Court was particularly
concerned that even the government recognized that many holders of an ATP could
not obtain a licit supply of marihuana but would have to resort to the black
market. Requiring medical users to obtain their supplies illicitly infringed
their liberty and security interests, which interests embraced a right of
reasonable access to a substance which the government acknowledges they may
possess and consume. It found that the principles of fundamental justice
include the recognition of the rule of law, and that state conduct which leads
to – indeed countenances - violation of the law is contrary to those
principles. Further, it applied the test of whether the restrictions furthered
some substantial and compelling collective interest, and it could find none. In
considering the government’s invocation of section 1 of the Charter, the
Court held that for similar reasons the restrictions imposed in the regulations
on access to marihuana for medical purposes were not rationally connected to
such legitimate objectives as the state had in controlling access to marihuana.
As a result, the Court struck down several provisions in the MMAR. We are only
concerned here with provisions concerning access by authorized persons. The Court
struck down subsection 41(b), the successor to which is in issue before me in
the present case. The Court also struck down the provisions on compensation for
DPPL’s and the limitations on them that they could only produce for one user
and could grow jointly with only two other producers.
[5]
On
December 3, 2003, the Governor in Council adopted several amendments to the
MMAR (see SOR/2003-387). While it repealed a number of provisions which the Court
in Hitzig had found to be invalid, including subsection 41(b), it
re-enacted subsection 41(b) in virtually identical terms as subsection 41(b.1)
which requires the Minister to refuse to issue a designated person production
license:
[if] the designated person would be the
holder of more than one licence to produce… .
It also
re-enacted, as section 54.1, previous section 54 which prohibited a DPPL from
producing in common with more than two other DPPL’s. It is the re-enacted
subsection 41(b.1) that the Applicants seek to have declared invalid for
essentially the same reasons as its predecessor was declared invalid in Hitzig
by the Ontario Court of Appeal.
[6]
The
Minister, however, lays some stress on the fact that on December 3, 2003 with
the coming into force of the amendments to the MMAR, Health Canada announced,
as referred to above, its Interim Policy on Distribution of Marihuana
Seeds and Dried Marihuana Product for Medical Purposes. This was designed
to give authorized persons reasonable access to a legal source of supply.
Essentially it facilitated ATP holders obtaining dried marihuana or seed from
the government’s contractor, PPS. It is not in dispute that as of the summer of
2007, fewer than 20% of persons with ATP’s were obtaining their marihuana from
PPS (in July, 2007, 392 out of a total of 1,983 ATP holders).
ANALYSIS
Introduction
[7]
The
issue before me is that of reasonable access to a supply of dried marihuana or
seed for those who already possess an authorization to possess marihuana. I
have some misgivings about the Court prescribing therapeutic substances which
are neither drugs approved under the elaborate and scientific processes of the Food
and Drug Act, and on which there is far from a scientific consensus as to
their benefits. But matters have moved well beyond that issue. The courts would
not find themselves in the business of prescribing medical treatment were it
not for the decision over 20 years ago that section 7 authorizes them, (see Re
B.C. Motor Vehicle Act, [1985] 2 S.C.R. 481), in the determination of what
is contrary to the principles of fundamental justice, to pass judgment not only
on the procedural fairness but also on the substantive correctness of the law.
But we must apply the constitution as the Supreme Court of Canada has found it
to be. It is clear that the Government of Canada has accepted, by adopting the
MMAR and the Interim Policy, (supra), that undue restraints on
access to marihuana for those to whom it has given authority to possess such
substance do attract the strictures of section 7 of the Charter. These
were the central findings by the Ontario Court of Appeal in the Parker
and Hitzig decisions (supra). It appears that the Crown never
sought to appeal Parker and an application for leave to appeal in the Hitzig
case was dismissed by the Supreme Court of Canada ([2004] S.C.C.A. No. 5), that
appeal apparently being framed on the correctness of the remedies chosen by the
Ontario Court of Appeal. After each of these decisions by the Ontario Court of
Appeal, the Government of Canada took steps to make its law and practices
conform to the Charter requirements identified by the Court. While the
Attorney General in the present case sought to argue again the applicability of
the principles of fundamental justice, it appears to me that the real issues in
dispute here are as to whether the remedial steps taken by the Government have
brought it into conformity with the Charter requirements identified in Parker
and Hitzig. The Attorney General has, correctly I believe, pointed out
that those requirements do not include an obligation on the part of government
to supply marihuana to medical users. What the Charter requires is that government
not hinder for no good reason those with demonstrated medical need to obtain
this substance.
Standard of
Review
[8]
While
neither party raised this issue, I take it that it is incumbent on me to
address it as this is a judicial review of a decision of the Minister or his
delegate with respect to applications for designation of a supplier. Such
decisions are of course reviewable under the Federal Courts Act without
any privative clause. The nature of the question is essentially one of
constitutional law. As such it is more amenable to authoritative determination
by the courts rather than the Minister. While the parties have put some facts
in issue, they were not facts which were put before the Minister: they are
“legislative” facts presented to assist the constitutional analysis in this
Court and are for determination by the Court. For these reasons I am satisfied
the standard of review of the Minister’s decision is correctness.
Issues
[9]
It
appears to me that there are essentially two questions for me to determine. First,
is subsection 41(b.1) contrary to the Charter? Second, in determining
this does the Interim Policy of December 3, 2003, whereby greater access
is provided to PPS product, provide a factual context in which subsection
41(b.1) can be seen as a permissible limitation on one form of supply, namely
that from designated producers?
[10]
I
am satisfied from the decisions of the Ontario Court of Appeal in Parker
and in Hitzig, supra, that subsection 41(b.1) is a restriction on
section 7 liberty and security rights of the Applicants. This is the subsection
which has been evoked by the Minister to prevent them from being able to choose
their designated producer, namely Carasel. In determining whether there is a
breach of section 7 of the Charter, one must first find an infringement
of an interest protected by section 7 and then consider whether, if there is a
restriction on that interest, it is in accordance with the principles of
fundamental justice. For the reasons given by the Ontario Court of Appeal in Hitzig
at paras. 97-104, I conclude that both the liberty and security interests of
the Applicants are negatively affected by subsection 41(b.1). As for the
liberty interests, “liberty” comprehends the right to make decisions of
fundamental personal importance. This would include the right to choose, on
medical advice, to use marihuana for treatment of serious conditions, that
right implying a right of access to such marihuana. It would also include the
right not to have one’s physical liberty endangered by the risk of imprisonment
from having to access marihuana illicitly. With respect to security, this
interest includes the similar right for those with medical need to have access
to medication without undue state interference.
[11]
In
determining whether these limits on section 7 interests are in accordance with
the principles of fundamental justice, one can consider whether the individual
rights in section 7 may nevertheless be subordinated to substantial and
compelling collective interests (see Hitzig, para. 119, and authorities
cited therein). Such a limitation, if it does little or nothing to enhance the
state’s interest, can be regarded as arbitrary: see Rodriguez v. British
Columbia (Attorney General) 1993 3 SCR 519 at page
594; R. v. Heywood (1994), 94 C.C.C. (3rd) 481 SCC at 514;
and Chaoulli v. Attorney General of Quebec, [2005] 1 S.C.R. 791 at
paras. 130, 131, 231. I believe that subsection 41(b.1) fails this test.
[12]
First
it must be observed that, according to the government’s own statistics, some
80% of persons with ATP’s who have been duly authorized to have and use
marihuana are not obtaining it from the government source, namely PPS. The
evidence shows that many users are unable to grow their own marihuana, either
because they are too ill or because their home circumstances do not make it
possible. While I have no statistics on the percentage of the market supplied
by DPPL’s, the regulations remain almost as restrictive as those which were
struck down by the Ontario Court of Appeal as creating an undue restraint on an
ATP’s recognized right to access. The Ontario Court of Appeal held that, by inference,
a large percentage of ATP’s were getting their marihuana from illicit sources.
The only things that have changed in this respect since that decision is the
amendment to the MMAR permitting designated producers to be compensated, and
the availability of marihuana and seeds from the government’s producer, PPS. I
will discuss the latter factor later.
[13]
The
government’s justification for re-enacting the previously invalidated subsection
41(b) as a new subsection 41(b.1) was stated in the Regulatory Impact Analysis
Statement published with the regulations of December 3, 2003 amending the MMAR.
That justification is as follows: (The reference to section 54 is not directly
relevant but shows the policy being pursued.)
Paragraph
41(b) will be re-enacted to reinstate on a national basis, the limit on the
number of persons for whom one designated person can produce marihuana; under
the MMAR, one DPL holder can cultivate for only one ATP holder; and
Section
54 will be re-enacted to reinstate on a national basis, the limit on the
number of DPL holders who can produce marihuana in common; under the MMAR, a
DPL holder is not permitted to produce marihuana in common with more than two
other DPL holders.
These
limits on the production of marihuana are necessary to:
-
maintain
control over distribution of an unapproved drug product, which has not yet
been demonstrated to comply with the requirements of the FDA/FDR;
-
minimize
the risk of diversion of marihuana for non-medical use;
-
be consistent
with the obligations imposed on Canada as a signatory to the United Nations’
Single Convention on Narcotic Drugs, 1961 as amended in 1972 (the 1961
Convention), in respect of cultivation and distribution of cannabis; and
-
maintain
an approach that is consistent with movement toward a supply model whereby
marihuana for medical purposes would be: subject to product standards;
produced under regulated conditions; and distributed through pharmacies, on
the advice of physicians, to patients with serious illnesses, when
conventional therapies are unsuccessful. Such a model would also include a
program of education and market surveillance.
|
L’alinéa
41b) sera remis en vigueur pour réintégrer au plan national la limite du
nombre de personnes pour lesquelles une personne désignée peut produire; en
vertu du RAMM, une seule personne désignée peut produire pour un seul
détenteur d’une autorisation de possession; et
L’article
54 sera remis en vigueur pour réintégrer au plan national la limite du nombre
de personnes désignées qui peuvent produire de la marihuana en commun; en
vertu du RAMM, un détenteur de licence de production à titre de personne
désignée n’est pas autorisé à produire de la marihuana en commun avec plus de
deux autres détenteurs.
Ces
limites sur la production de marihuana sont nécessaires pour :
-
maintenir
le contrôle sur la distribution d’une drogue non approuvée, dont la
conformité aux exigences de la LAD et du RAD n’a pas encore été démontrée;
-
minimiser
le risque de détournement de la marihuana à des fins non médicales;
-
être
compatible avec les obligations du Canada comme signataire de la Convention
unique sur les stupéfiants des nations Unies de 1961, telle que modifiée en
1972 (la convention de 1961), concernant la culture et la distribution de
cannabis; et
-
maintenir
une approche qui est compatible avec le mouvement vers un modèle
d’approvisionnement selon lequel la marihuana à des fins médicales serait
assujettie à des normes du produit, serait produite sous des conditions
réglementées et serait distribuée par les pharmacies, sur avis des médecins,
aux patients gravement malades lorsque les thérapies conventionnelles
échouent. Un tel modèle comprend également un programme d’éducation et la
surveillance du marché.
|
In its argument, the government has essentially
adopted this rationale for the re-enactment of subsection 41(b.1). It is
therefore necessary to consider whether such reasons provide a basis for saying
that subsection 41(b.1) is in accordance with the principles of fundamental
justice. In the particular context of this case I will consider criteria such
as that adopted by the Ontario Court of Appeal in Hitzig, supra,
at paras. 109-28, holding that fundamental justice requires respect for the
rule of law and thus cannot countenance a system which forces authorized
medical users of dried marihuana to obtain it illicitly. Also I will have
regard to the question of whether the limitation in subsection 41(b.1) is
arbitrary, not genuinely connected to the protection of the interests of the
state. In this, I rely on the authority of cases such as Rodriguez and Chaoulli,
cited above with relevant passages.
[14]
The
first justification offered by the Respondent for subsection 41(b.1) as set out
in the 2003 regulatory impact statement quoted above, is that such a
restriction on designated producers limiting them to produce for only one user
is for the purpose of maintaining control over distribution of an unapproved
drug product. It has not been demonstrated to me why limiting the production of
a designated producer to one customer will have this effect. The Regulations
only permit such producer to produce marihuana for persons already authorized
by the Minister to possess and use marihuana: that is, holders who have an ATP
license. ATP holders are persons adjudged by the Minister to be legitimate
users of this “unapproved drug” and whether the producer grows for one ATP
holder or thirty ATP holders the distribution of marihuana would be to persons,
and for purposes, already countenanced by the regulations. Some mention was
made of quality control being jeopardized if designated producers could produce
for more than one customer. I am unaware that Health Canada imposes any quality
control on designated producers now but if it does, or even if it does not, it
can put in place the same kind of quality controls for designated producers
with one or many customers. Indeed it seems logical that if designated
producers were authorized to produce for many customers there would be economies
of scale and a level of income that might make possible even better quality
control by the producer. At the same time, a host of one-customer designated
producers would be made unnecessary and therefore any control and inspection
system Health Canada might wish to impose on
designated producers would be simpler and cheaper to operate with fewer
producers.
[15]
As a
second rationale, it is said by the government that subsection 41(b.1) will
“minimize the risk of diversion of marihuana for non-medical use”. That, too,
has not been explained to my satisfaction. Again, designated producers, no
matter how many customers they have, must confine their sales to persons with
an ATP. A designated producer, since he is authorized to grow marihuana now,
has a present potential for producing more than his one customer needs and
diverting the surplus for illicit sale. This would be true whether he grows for
one customer or twenty-five. I suppose that it might be easier, in a grow
operation large enough to supply twenty-five legitimate customers, to conceal a
larger potential surplus of production for illicit sale. This is hypothetical
and it might equally be said that, as noted above, with fewer designated
producers having larger operations, a system of inspection would be much easier
to sustain than in the present plethora of single-customer producers. The
government also argues that a larger grow operation run by a designated
producer with multiple customers would, because of its size, attract theft. But
it is also argued by the Applicants that a larger operation, because of
efficiencies of scale, could have a better security system and indeed could be
more secure than the typical home-based self producer or single-customer
designated producer.
[16]
At
this point it may be observed, in respect of both the first and second rationales
that it may well be that there could be justification for limiting the size of
operations of designated producers, to facilitate supervision and inspection
for quality and security. But any new regulations to this end will have to be
justified as having a demonstrable purpose rationally related to legitimate state
interests. No such justification has been offered to me for subsection 41(b.1).
[17]
As
the third justification for subsection 41(b.1) the government has invoked the
United-Nation’s Single Convention on Narcotic Drugs, 1961 which, the
government says, imposes on it obligations “in respect of cultivation and
distribution of cannabis…” I have studied the convention and the affidavit of
the Minister’s witness on this subject and remain puzzled. The convention
appears to require the Government of Canada to control marihuana as a narcotic
drug and to limit its use to medical and scientific purposes. It requires a medical
prescription for the supply or dispensation of drugs to individuals and a
system of limiting quantities of drugs available to them. It requires that
Canada maintain a system to control all persons and enterprises engaged in the
trade or distribution of drugs which must be carried out under license. It
would appear that Canada complies with these
requirements except for the requirement of a prescription for any cannabis authorized
for individual medical use, although the MMAR system may constitute an adequate
substitute. The Minister lays particular stress on Article 23 of the Convention
which requires that a state permitting the cultivation of marihuana have an Agency
to carry out functions under that article. Paragraph 2(d) of Article 23
requires that cultivators of marihuana be required to deliver their total crops
to the Agency. According to the Minister, Health Canada has been designated as
the Agency for Canada. The Minister argues as
follows:
To
allow growers to supply to more than one person who is authorized to possess
and use marihuana for medical purposes would obligate the Government, in
compliance with the 1961 Convention, to collect all marihuana produced.
This appears to me to be
a non sequitur. If the convention requires that all “cultivators” of
marihuana must deliver their “total crops” to the Agency (as Article 23
specifies) then presumably holders of PPL’s and DPPL’s, even though they
produce for one person, should deliver their “total crops” to Health Canada.
That is not done: the MMAR contemplates that production is consumed by a user,
whether produced by himself or by his designated producer. I have failed to see
how allowing a designated producer to produce for multiple users creates some
new problem vis-à-vis the Convention which does not already exist. Counsel
agreed that the Convention has not been made part of the law of Canada as such although parts
of it have been implemented by Canadian law. To the extent that the MMAR, if
they were to permit the holder of the TPL to produce for more than one ATP
holder, might conflict with the Convention, this domestic law must prevail over
an unimplemented international treaty. Further if to follow the requirements of
the Convention were to conflict with Canadian constitutional requirements such
as the guarantees in section 7 of the Charter then the Canadian
constitution must prevail in this Court.
[18]
Fourthly,
the government says that subsection 41(b.1) is necessary to “maintain an
approach that is consistent with movement toward a supply model” whereby
medical marihuana would be produced and made available like other therapeutic
drugs, on prescription and through pharmacies. That may well be a laudable goal
and if ever reached would make unnecessary litigation such as the present case.
But we do not know when this new age will dawn and in the meantime the courts,
in their wisdom, have concluded that persons with serious conditions for which
marihuana provides some therapy should have reasonable access to it. It is no
answer to say that someday there may be a better system. Nor does the hope for
the future explain why a designated producer must be restricted to one
customer.
[19]
Consequently,
I have concluded that the restraint on access which subsection 41(b.1) provides
is not in accordance with the principles of fundamental justice. First, it does
not adequately respond to the concerns motivating the Ontario Court of Appeal
judgment in Hitzig: that is it leaves those ATP holders who cannot grow
for themselves and who cannot engage a designated producer because of the
restrictions imposed on the latter by the MMAR, to seek marihuana in the black
market. The Ontario Court of Appeal said that this is contrary to the rule of
law, to pressure a citizen to break the law in order to have access to
something he medically requires. The only factor which has changed since the Hitzig
case arose is the advent of PPS as a licensed dealer. The Minister argues that
any ATP holder, who cannot grow for himself or cannot find a designated
producer prepared to dedicate himself solely to that ATP holder, may obtain his
dried marihuana or seed from a government contractor, namely PPS. That
certainly does provide an alternative avenue of access. But the evidence shows
that after four years of this new policy of the government supply of marihuana,
fewer than 20% of ATP holders resort to it. The Applicants take the position
that the PPS product is inferior and not to the taste of most users. They say
that PPS only makes available one strain of marihuana for medical use whereas
there are several strains which have different therapeutic effects depending on
the condition of the user. The evidence as to the quality of the PPS product
was almost all hearsay and anecdotal. The expert scientific evidence as to the
different therapeutic effects of various strains mainly indicates that there is
great uncertainty and the subject requires further research. I am therefore not
prepared to lead a judicial incursion into yet another field of medicine and
pass judgment on the quality of the PPS product. In my view it is not tenable
for the government, consistently with the right established in other courts for
qualified medical users to have reasonable access to marihuana, to force them
either to buy from the government contractor, grow their own or be limited to
the unnecessarily restrictive system of designated producers. At the moment,
their only alternative is to acquire marihuana illicitly and that, according to
Hitzig, is inconsistent with the rule of law and therefore with the
principles of fundamental justice.
[20]
I
also find that subsection 41(b.1) is inconsistent with the principles of
fundamental justice because it is arbitrary in the sense that it causes
individuals a major difficulty with access while providing no commensurate
furtherance of the interests of the state.
[21]
For
these reasons I find subsection 41(b.1) to infringe the Applicants’ rights to
liberty and security under section 7 of the Charter and therefore to be
invalid.
[22]
In
written submissions the Respondent invoked, as an alternative, section 1 of the
Charter. His position is even more difficult under section 1 as there he
has the onus of establishing that such a limitation is demonstrably justified.
His argument in this respect adds little to the justification offered under section
7. Assuming that there are some legitimate objectives being pursued by adoption
of the MMAR, for the same reasons that I found subsection 41(b.1) to be
arbitrary and thus contrary to the principles of fundamental justice I find
that it is not rationally connected to the objectives stated for it and its
restraint is disproportional to any state interests promoted.
[23]
The
Applicants argued certain other grounds which I will not go into in any detail.
It was argued that the current regulations were adopted without adequate
consultation with the “stakeholders” and therefore they are invalid. The
evidence did not entirely support the claim of no consultation, and in any
event, I know of no authority for the proposition that there is a
constitutional requirement in the legislative process for consultation to occur
with parties who may have an interest. However desirable consultation may be,
it has not yet become a constitutional imperative in the legislative process.
The Applicants also cited to me the recent case of R. v. Long, [2007] O.J.
No. 2774 (Ont.
Ct.). In
this case an Ontario Court judge held invalid subsection 4(1) of the Control
Drugs and Substances Act, supra, which prohibits the possession of
marihuana because in his view, the Government of Canada had not yet adequately
removed barriers to access. The MMAR still limits access. While the policy
adopted in 2003 could make it possible for anyone in need of marihuana to
obtain it from PPS, the government contractor, the learned judge did not
consider this to be enough because that policy is not expressed in law.
Therefore, while persons who have a constitutional right to access might in
fact get it through PPS, they could not be said to have a legal right to that
access, only the benefit of an administrative policy permitting it. I do not
intend to deal with this case further. It is under appeal. Further, I have
found that the unnecessary restrictions on access in subsection 41(b.1) cannot
be overcome by a forced monopoly for PPS product for those who cannot grow for
themselves or find an available designated producer. Therefore the question of
whether the policy should be embodied in law is not relevant to my finding.
[24]
In
conclusion, it can be said that the Minister in assuming the validity of
subsection 41(b.1) did not take a correct view of the law.
REMEDIES
[25]
The
Applicants requested that I declare subsection 41(b.1) of the MMAR to be of no
force or effect on the basis that it violates section 7 of the Charter of
Rights and Freedoms. I will so declare. They have also requested that, in
lieu of their original request for mandamus, I refer their applications
for the designation of Carasel as their producer back to the Minister for
reconsideration consistently with my reasons. I will so direct.
[26]
Further,
the Applicants have asked that I should, under subsection 24(1) of the Canadian
Charter of Rights and Freedoms,
retain
supervisory jurisdiction over Health Canada’s creation and implementation of a
new process for allowing multiple patients to designate a single designated
producer by requiring Health Canada to submit periodic reports on the status
and progress of the new process…
The Applicants mainly rely on the decision of
the Supreme Court of Canada in Glenda Doucet-Boudreau et al. v. Attorney
General of Nova Scotia, [2003] 3 S.C.R. 3 where, by a majority of 5-4, that
Court reversed the Court of Appeal of Nova Scotia and upheld the decision of
the trial judge to retain such jurisdiction. He had declared that francophones
in five school districts in Nova Scotia were entitled to “homogeneous French-language facilities
and programs at the secondary school level”. While the Government of Nova
Scotia did not deny the entitlement of the Plaintiffs to such facilities under
section 23 of the Constitution Act, 1982, some years had passed
without those facilities being provided. In his judgment declaring the
entitlement, the trial judge ordered the respondents to use their best efforts
to comply with the orders requiring these facilities to be provided, and the Court
retained jurisdiction to hear reports from the respondents respecting their
compliance with this order. This order was set aside by the Nova Scotia Court
of Appeal, on the grounds that the trial judge was functus officio once
he made the order and could not continue “supervisory jurisdiction”. The
majority in the Supreme Court of Canada reversed this decision. The Court
listed several considerations which should be taken into account when deciding
whether to retain supervisory jurisdiction. It also said that in this case the
trial judge was not functus officio because although continuing a
supervisory role he did not purport to retain any jurisdiction to change the
declarations of entitlement.
[27]
I am
not persuaded that I should retain supervisory jurisdiction in this case.
First, it should be noted that the Doucet-Boudreau case did not involve
a determination under subsection 52(1) of the Constitution Act, 1982
that a law is invalid, as does the present case. In Doucet-Boudreau, the
duty owed under section 23 of that Act was not in dispute, only its
implementation and this was a remedial order under subsection 24(1) of the Constitution
Act, 1982, a matter of implementation by the construction of
facilities and the organization of courses to comply with the requirements of
the declaration. In the present case I am making a declaration of invalidity
under subsection 52(1) of the Constitution Act, 1982. That
declaration will be self-executing, making invalid subsection 41(b.1) of the
MMAR. As I have signaled in my Reasons, I cannot preclude the Governor in
Council amending the Regulations yet again if to do so it would achieve some
legitimate goal while preserving reasonable access by ATP holders to marijuana.
That is always a possibility after every declaration of invalidity. But the
Supreme Court of Canada, both the majority and the minority, in Doucet-Boudreau
recognized that one of the factors to be taken into account in choosing a
remedy of supervisory jurisdiction is the separation of powers. What would be
required of me if I were to retain supervisory jurisdiction would be the
monitoring of future legislation and, if such jurisdiction were to be of any
use to the Applicants, I would have to exercise a veto over new proposed regulations
which appear to me to be inconsistent with that right of access. Under the
circumstances, I do not think that is appropriate and I will not so order.
[28]
The
Applicants will, of course, be entitled to their costs.
JUDGMENT
THIS COURT HEREBY ORDERS
AND ADJUDGES that
1.
Subsection
41(b.1) of the Marihuana Medical Access Regulations, SOR/2001-227 as
amended be declared invalid as contrary to section 7 of the Canadian Charter
of Rights and Freedoms;
2.
The
refusal of the applications by the Applicants for designated-person production
licenses designating Carasel Harvest Supply Corporation as their designated
producer be set aside and these matters be referred back to the Minister for
reconsideration in accordance with these Reasons;
3.
The
Applicants be awarded costs.
“Barry
L. Strayer”